Market open
FibroGen/$FGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About FibroGen
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
Ticker
$FGEN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
225
ISIN
US31572Q8087
Website
FibroGen Metrics
BasicAdvanced
$31M
-
-$0.10
-
-
Price and volume
Market cap
$31M
52-week high
$1.53
52-week low
$0.18
Average daily volume
706K
Financial strength
Current ratio
2.024
Quick ratio
0.46
Long term debt to equity
-52.146
Total debt to equity
-52.146
Interest coverage (TTM)
-11.48%
Management effectiveness
Return on assets (TTM)
-22.73%
Return on equity (TTM)
66.92%
Valuation
Price to revenue (TTM)
4.34
Price to book
-0.14
Price to tangible book (TTM)
-0.14
Growth
Revenue change (TTM)
-95.82%
Earnings per share change (TTM)
-95.93%
3-year revenue growth (CAGR)
-69.95%
3-year earnings per share growth (CAGR)
-68.00%
What the Analysts think about FibroGen
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for FibroGen stock.
FibroGen Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
FibroGen Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
FibroGen News
AllArticlesVideos
FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript
Seeking Alpha·4 days ago
Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)
GlobeNewsWire·1 week ago
FibroGen to Report First Quarter 2025 Financial Results
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for FibroGen stock?
FibroGen (FGEN) has a market cap of $31M as of May 16, 2025.
What is the P/E ratio for FibroGen stock?
The price to earnings (P/E) ratio for FibroGen (FGEN) stock is 0 as of May 16, 2025.
Does FibroGen stock pay dividends?
No, FibroGen (FGEN) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next FibroGen dividend payment date?
FibroGen (FGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for FibroGen?
FibroGen (FGEN) does not currently have a Beta indicator.